HER2-positive breast cancer and tyrosine kinase inhibit

Npj Breast Cancer
7, 56
DOI: 10.1038/s41523-021-00265-1

Citation Report

#	Article	IF	Citations
1	Trans-(â˜)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?. Molecules, 2021, 26, 4537.	1.7	5
2	Zinc Signaling in the Mammary Gland: For Better and for Worse. Biomedicines, 2021, 9, 1204.	1.4	4
3	Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer. Cancers, 2021, 13, 4685.	1.7	34
4	Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Bloodâ€“Brain Barrier. Pharmaceutics, 2021, 13, 1446.	2.0	11
5	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. Frontiers in Immunology, 2021, 12, 786286.	2.2	8
6	Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. Biomolecules, 2022, 12, 72.	1.8	18
7	Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. Journal of Biological Chemistry, 2022, 298, 101525.	1.6	9
8	Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210852.	1.4	4
9	Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Frontiers in Molecular Biosciences, 2022, 9, 847835.	1.6	41
10	New and Emerging Targeted Therapies for Advanced Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 2288.	1.8	55
11	Synthesis and evaluation of novel HER-2 inhibitors to exert anti-breast cancer ability through epithelial-mesenchymal transition (EMT) pathway. European Journal of Medicinal Chemistry, 2022, 237, 114325.	2.6	3
12	Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 745-752.	2.3	7
13	Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Frontiers in Cardiovascular Medicine, 2022, 9, 847012.	1.1	36
14	Chemoenzymatic Synthesis of Original Stilbene Dimers Possessing Wnt Inhibition Activity in Triple-Negative Breast Cancer Cells Using the Enzymatic Secretome of Botrytis cinerea Pers.. Frontiers in Chemistry, 2022, 10, 881298.	1.8	7
15	Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Cancer Control, 2022, 29, 107327482210992.	0.7	11
16	The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation. Applied Sciences (Switzerland), 2022, 12, 4622.	1.3	1
17	Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review. Cancer Treatment Reviews, 2022, 108, 102418.	3.4	14
18	Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. ESMO Open, 2022, 7, 100501.	2.0	12

#	Article	IF	Citations
19	The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Military Medical Research, 2022, 9, .	1.9	5
20	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers, 2022, 14, 3305.	1.7	11
21	Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study. Frontiers in Oncology, 0, 12, .	1.3	4
22	Lapatinib loaded exosomes as a drug delivery system in breast cancer. Journal of Drug Delivery Science and Technology, 2022, 75, 103584.	1.4	11
23	Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. Breast, 2022, 66, 145-156.	0.9	3
24	Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage. Current Oncology, 2022, 29, 6053-6067.	0.9	5
25	Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer. Cancer Prevention Research, 2022, 15, 791-802.	0.7	3
26	Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness. Frontiers in Endocrinology, 0, 13, .	1.5	8
27	Therapeutics targeting the metastatic breast cancer bone microenvironment. , 2022, 239, 108280.		8
28	Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment. Cancer Informatics, 2022, 21, 117693512211278.	0.9	2
29	ErbB4 in the brain: Focus on high grade glioma. Frontiers in Oncology, 0, 12, .	1.3	4
30	Genomic mapping of copy number variations influencing immune response in breast cancer. Frontiers in Oncology, 0, 12, .	1.3	0
31	<scp>Aptamerâ€siRNA</scp> chimeras: Promising tools for targeting <scp>HER2</scp> signaling in cancer. Chemical Biology and Drug Design, 2023, 101, 1162-1180.	1.5	1
32	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers, 2022, 14, 4543.	1.7	9
33	Î²-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features. Cancer Cell International, 2022, 22, .	1.8	6
34	Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	9
35	Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharmaceutica Sinica B, 2023, 13, 955-966.	5.7	6
36	Chemotherapeutic Protocols for the Treatment of Breast Cancer. , 2022, , 79-123.		0

#	Article	IF	Citations
37	Antitumor activity of the protein kinase inhibitor 1-(Î²-D-2â€²-deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole in breast cancer cell lines. BMC Cancer, 2022, 22, .	1.1	1
38	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
39	Molecular targeted therapy for anticancer treatment. Experimental and Molecular Medicine, 2022, 54, 1670-1694.	3.2	57
40	Precision medicine: the precision gap in rheumatic disease. Nature Reviews Rheumatology, 2022, 18, 725-733.	3.5	15
41	Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A. Frontiers in Immunology, 0, 13, .	2.2	5
42	Synthesis and antiproliferative activity of 1H-1,2,3-triazole-4H-chromene-<scp>d</scp>-glucose hybrid compounds with dual inhibitory activity against EGFR/VEGFR-2 and molecular docking studies. New Journal of Chemistry, 2022, 46, 23179-23197.	1.4	2
43	Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. Advances in Clinical Chemistry, 2023, , 119-153.	1.8	1
44	Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery, 2023, 22, 101-126.	21.5	140
45	Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. Pharmaceuticals, 2022, 15, 1452.	1.7	2
46	The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions. Cancers, 2022, 14, 6173.	1.7	3
47	Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis. Breast Cancer: Targets and Therapy, 0, Volume 14, 491-504.	1.0	0
48	Prioritization of bioactive compounds envisaging yohimbine as a multi targeted anticancer agent: insight from molecular docking and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 0, , 1-15.	2.0	0
49	Binary and ternary inclusion complexation of lapatinib ditosylate with Î²-cyclodextrin: preparation, evaluation and in vitro anticancer activity. Beni-Suef University Journal of Basic and Applied Sciences, 2022, 11, .	0.8	5
50	PTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survival. Clinical Breast Cancer, 2023, 23, e131-e139.	1.1	3
51	Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. Systematic Reviews, 2022, 11, .	2.5	4
52	Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Frontiers in Pharmacology, 0, 13, .	1.6	3
53	Heterogeneity in hormone-dependent breast cancer and therapy: Steroid hormones, HER2, melanoma antigens, and cannabinoid receptors. Advances in Cancer Biology Metastasis, 2023, 7, 100086.	1.1	5
54	Hornerâ€“Wadsworthâ€“Emmons reaction as an excellent tool in the synthesis of fluoro-containing biologically important compounds. Organic and Biomolecular Chemistry, 2023, 21, 1095-1120.	1.5	4

#	Article	IF	Citations
55	Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PLoS ONE, 2023, 18, e0279775.	1.1	1
56	Epigeneticâ€“Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer. Cancer Research, 2023, 83, 657-666.	0.4	4
58	Kinase Inhibitors in Genetic Diseases. International Journal of Molecular Sciences, 2023, 24, 5276.	1.8	0
59	Design, synthesis, and antiproliferative properties of new 1,2,3-triazole-carboximidamide derivatives as dual EGFR/VEGFR-2 inhibitors. Journal of Molecular Structure, 2023, 1282, 135165.	1.8	9
60	Nanotechnology Approaches for Prevention and Treatment of Chemotherapyâ€Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors. Small, 0, , .	5.2	4
61	Targeting Breast Cancer: An Overlook on Current Strategies. International Journal of Molecular Sciences, 2023, 24, 3643.	1.8	15
62	Integrin Î±vÎ²3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer. Cancers, 2023, 15, 1216.	1.7	4
63	Development of a bispecific DNA-aptamer-based lysosome-targeting chimera for HER2 protein degradation. Cell Reports Physical Science, 2023, 4, 101296.	2.8	5
64	HER Receptor, Current, and Emerging Therapeutic Targets. , 2023, , 1-32.		0
65	Novel Arylsulfonylhydrazones as Breast Anticancer Agents Discovered by Quantitative Structure-Activity Relationships. Molecules, 2023, 28, 2058.	1.7	4
66	The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer. Frontiers in Pharmacology, 0, 14, .	1.6	1
67	UPLC-MS/MS Method for Simultaneous Estimation of Neratinib and Naringenin in Rat Plasma: Greenness Assessment and Application to Therapeutic Drug Monitoring. Separations, 2023, 10, 167.	1.1	1
68	Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines. Investigational New Drugs, 0, , .	1.2	0
69	Targeting CLDN6 in germ cell tumors byÂan antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. Molecular Medicine, 2023, 29, .	1.9	3
70	Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression. Archives of Pathology and Laboratory Medicine, 2024, 148, 242-255.	1.2	3
71	How valuable can proteogenomics be in clinical breast cancer research?. Expert Review of Proteomics, 0, , 1-4.	1.3	1
72	Novel Functionalized Spiro [Indoline-3,5â€²-pyrroline]-2,2â€²dione Derivatives: Synthesis, Characterization, Drug-Likeness, ADME, and Anticancer Potential. International Journal of Molecular Sciences, 2023, 24, 7336.	1.8	3
89	Clinical implementation of biomarkers and signaling pathway as novel targeted therapeutics in breast cancer. , 2023, , 27-56.		0

#	Article	IF	Citations
101	Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma. Oncogenesis, 2023, 12, .	2.1	0
110	Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer. Cancer Treatment and Research, 2023, , 237-281.	0.2	0
111	Role of Drug Receptors in Pharmacogenomics. , 2023, , 77-88.		0